Evaluation method for improving Alzheimer's disease through ergothioneine and application

By verifying the role of ergothione in inhibiting Aβ-induced toxicity and H2O2-induced cell damage, it comprehensively evaluates its ability to prevent and relieve Alzheimer's disease and applies it in drugs, solving the problem of incomplete evaluation methods and achieving the goal of achieving The multi-faceted improvement effect on Alzheimer's disease provides scientific basis for the field of food nutrition and health.

CN118903480AInactive Publication Date: 2024-11-08SHAANXI UNIV OF SCI & TECH

Patent Information

Application Number
CN202411024555.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Alzheimer's disease evaluation method is not comprehensive, and it is difficult to comprehensively evaluate the prevention and mitigation ability of ergothione to the disease.

Method used

By verifying the role of ergothione in inhibiting Aβ-induced toxicity and H2O2-induced cell damage, it demonstrates its preventive and remission ability for Alzheimer's disease, and uses it as a functional component of anti-Alzheimer's disease in drugs.

Benefits of technology

Comprehensively evaluated the improvement effect of ergothione on Alzheimer's disease, demonstrating that it is in multiple angles (inhibition of Aβ-induced toxicity, inhibition of H2O2-induced cell damage, improvement of cell morphology, reduction of apoptotic cells, inhibition of inflammatory marker expression, inhibition of Impaired nerve cells and improved cognitive learning ability) in preventing and relieving Alzheimer's disease, providing scientific basis for the field of food nutrition and health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004968166950000011
    Figure HDA0004968166950000011
  • Figure HDA0004968166950000021
    Figure HDA0004968166950000021
  • Figure HDA0004968166950000031
    Figure HDA0004968166950000031
Patent Text Reader

Abstract

The invention discloses an evaluation method for improving Alzheimer's disease by using ergothioneine, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, caenorhabditis elegans CL4176 is adopted as a toxicity model for reflecting A beta induction in the Alzheimer's disease, a H2O2-induced human-derived microglial cell HMC3 oxidative damage model is constructed, and a double-transgenic APP / PS1 mouse model is adopted, so that the prevention and alleviation effects of the keratinothioneine on the Alzheimer's disease are demonstrated from multiple angles; the improvement effect of the ergothioneine on the Alzheimer's disease is comprehensively evaluated, a scientific basis is provided for application of the functional component ET in the field of food nutrition and health, and the application value of food molecular nutriology in challenges of global aging and neurodegenerative diseases is highlighted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an evaluation method and application of ergothioneine in improving Alzheimer's disease. Background Art

[0002] Alzheimer's disease (AD) is the most common cause of senile dementia and is widely considered to be a manifestation of Alzheimer's disease. As a typical neurodegenerative disease, the main clinical features of AD include persistent memory loss and changes in personality and behavior observed in some cases. According to statistics, the number of AD patients worldwide is expected to increase to 66 million in 2030 and further rise to approximately 131 million in 2050. In addition, the increasing aging of the population heralds an increase in the number of AD patients, which will have a profound impact on the healthcare system, economy and social structure.

[0003] Ergothioneine (ET) is naturally present in many foods, such as mushrooms, black beans and red beans, offal and cereals. So far, there have been no reports of unsafe ET applications. Rats were well tolerated when they were given oral doses of up to 1600 mg / kg of L-ET for 90 days, with no adverse effects on weight gain, food consumption rate, clinical pathology and related histopathological changes. The blood-brain barrier (BBB) ​​can prevent harmful substances such as toxins and pathogens from entering the brain tissue from the blood, and has important biological significance for maintaining the homeostasis of the central nervous system. It is also because the BBB prevents many drugs from reaching the brain, and the effective delivery of drugs is also a challenge in the treatment of AD. However, ET in the diet can cross the blood-brain barrier and has been detected in human cerebrospinal fluid and postmortem brain samples. In addition, the uptake of ET requires the transporter OCTN1, and the expression of this special transporter OCTN1 can be observed in the brain and various nerve cells. The ability of ET to cross the blood-brain barrier indicates that ET has the potential to play a functional role in the central nervous system.

[0004] Existing studies have shown that ET has certain anti-AD effects, but the evaluation of ET's anti-AD activity is not comprehensive. Summary of the invention

[0005] The object of the present invention is to provide an evaluation method and application of ergothioneine for improving Alzheimer's disease, so as to solve the technical problem that the existing evaluation method is not comprehensive.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The invention discloses an evaluation method for improving Alzheimer's disease by using ergothioneine, verifies the effects of ergothioneine on inhibiting Aβ-induced toxicity and inhibiting H2O2-induced cell damage, and demonstrates the ability of ergothioneine to prevent and alleviate Alzheimer's disease.

[0008] Furthermore, when inhibiting Aβ-induced toxicity, the ergothioneine is used at a concentration of 1 to 25 mmol / L.

[0009] Furthermore, it inhibited H2O2-induced cell damage, improved cell morphology and reduced the number of apoptotic cells.

[0010] Furthermore, the cells are microglia.

[0011] Furthermore, when inhibiting H2O2-induced cell damage, the concentration of ergothioneine used was 150 to 2400 μmol / L.

[0012] Furthermore, it also includes verifying the effects of ergothioneine in inhibiting the expression of inflammatory markers, inhibiting nerve cell damage and improving cognitive learning ability.

[0013] Furthermore, the use concentration of the ergothioneine is 20 to 40 mg / kg / day.

[0014] The invention also discloses the application of ergothioneine in preparing an anti-Alzheimer's disease drug.

[0015] Furthermore, the dosage form of the drug includes one or more of tablets, capsules, granules, solutions or injections.

[0016] Furthermore, the dosage of ergothioneine in the tablet, capsule, granule, solution or injection is 160 to 1280 mg / kg / day.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The invention discloses an evaluation method for using ergothioneine in the fight against Alzheimer's disease, demonstrates the preventive and alleviating effects of ergothioneine on Alzheimer's disease from multiple perspectives, comprehensively evaluates the improving effect of ergothioneine on the fight against Alzheimer's disease, provides a scientific basis for the application of the functional component ET in the field of food nutrition and health, and highlights the application value of food molecular nutrition in the challenges of global aging and neurodegenerative diseases.

[0019] Furthermore, nematode, cell and mouse models were used to demonstrate and evaluate the improvement effects of ergothioneine in inhibiting Aβ-induced toxicity, inhibiting H2O2-induced cell damage, improving cell morphology and reducing the number of apoptotic cells, inhibiting the expression of inflammatory markers, inhibiting nerve cell damage, and improving cognitive learning ability, and thereby comprehensively evaluating the improvement effect of ET on AD symptoms.

[0020] Furthermore, ergothioneine is naturally present in many foods, has good safety, has no adverse reactions after consumption, and easily crosses the blood-brain barrier, exerting functional application potential in the human central nervous system. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The effects of lentinan (LP), lentinan (LNT) and ET on Aβ-induced toxicity in CL4176 nematodes;

[0022] Among them: a-The effects of LP, LNT and ET on the paralysis rate of nematodes; b-The effects of different concentrations of ET on the paralysis rate of CL4176 nematodes; c-The level of reactive oxygen species (ROS) in CL4176 nematodes after treatment with 25mmol / L ET; d-The effects of different concentrations of ET on the lifespan of CL4176 nematodes;

[0023] Figure 2 Effects of different concentrations of ET pretreatment on HMC3 cell viability induced by different concentrations of H2O2;

[0024] Figure 3 The effect of different concentrations of ET pretreatment on the morphology of HMC3 cells treated with 100 μmol / L H2O2 for 24 h (100×);

[0025] Figure 4 The effects of ET intake for 6 months on body weight, water intake and organ indexes of APP / PS1 mice;

[0026] Figure 5 The effect of ET on the success rate of Y-maze alternation in APP / PS1 mice;

[0027] Wherein: a, b and c are the alternation success rates of mice in the Y-maze at 3, 6 and 9 months of age, respectively; d-the alternation success rates of mice in the AD group at 3, 6 and 9 months of age in the Y-maze;

[0028] Figure 6 The effect of ET on the total distance traveled by APP / PS1 mice in the open field;

[0029] Figure 7 The effect of ET on the novel object exploration time of APP / PS1 mice;

[0030] Figure 8The effect of ET on HE staining of brain tissue of APP / PS1 mice;

[0031] Among them: Whole brain refers to the whole brain area; Cortex refers to the mouse cerebral cortex area; CA1, DG and CA3 refer to the CA1 area, DG area and CA3 area of ​​the mouse hippocampus respectively; scale bars are 2000 and 200 μm;

[0032] Fig. 9 The effect of ET on Nissl staining of brain tissue of APP / PS1 mice;

[0033] Among them: Whole brain refers to the whole brain area; Cortex refers to the mouse cerebral cortex area; CA1, DG and CA3 refer to the CA1 area, DG area and CA3 area of ​​the mouse hippocampus respectively; scale bars are 2000 and 200 μm;

[0034] Fig.10 The effect of ET on thioflavin staining in brain tissue of APP / PS1 mice;

[0035] Among them: Whole brain refers to the whole brain area; Cortex and Hippocampus refer to the cerebral cortex and hippocampus of mice respectively; scale bars are 2000, 500 and 200 μm;

[0036] Fig.11 The effect of ET on Aβ deposition in the brain tissue of APP / PS1 mice;

[0037] Wherein: a-average fluorescence intensity of Aβ in mouse brain tissue; b-Aβ immunofluorescence in the cortex, whole brain and hippocampus of mouse brain tissue; scale bars are 2000, 500 and 200 μm;

[0038] Fig.12 The effect of ET on the expression of Iba-1 in the brain tissue of APP / PS1 mice;

[0039] Among them, the scale bars are 2000, 500, and 200 μm;

[0040] Fig.13 The effect of ET on the expression of antioxidant and inflammatory related proteins in the brain tissue of APP / PS1 mice;

[0041] Among them: a-the expression bands of antioxidant and inflammation-related proteins in the brain tissue of each group of mice; b, c, d, e and f are the relative protein expression levels of NRF2, HO-1, NQO1, TNF-α and 1L-1β, respectively. DETAILED DESCRIPTION

[0042] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0043] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0044] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0045] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”

[0046] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0047] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0048] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples are conventional commercial products unless otherwise specified, and their specifications are conventional specifications in the art. In the specification of the present invention and the following examples, unless otherwise specified, "%" means weight percentage, "part" means weight part, and ratio means weight ratio.

[0049] Example 1

[0050] Protective effect of ergothioneine in alleviating Aβ-induced toxicity in CL4176 nematodes:

[0051] CL4176 nematode paralysis assay: CL4176 nematodes synchronized to the L3 stage were transferred to NGM plates treated with LP, LNT and ET, respectively, and incubated at 16°C for 24 hours. The temperature was then raised to 25°C for 24 hours to stimulate the expression of Aβ in muscle cells; (the CL4176 nematodes were considered paralyzed if they failed to move during the observation period and showed cleared bacteria around the head, or if eggs accumulated near the body, or if they could not complete a complete sinusoidal movement when touched with a platinum wire); the number of paralyzed CL4176 nematodes was recorded every 2 hours until all nematodes were paralyzed;

[0052] Determination of ROS levels in CL4176 nematodes: The synchronized L3 stage CL4176 nematodes were first transferred to NGM medium containing 25mmol / L ET and coated with E.coli OP50, and cultured at 25°C for 36h to determine the in vivo ROS levels; the CL4176 nematodes were transferred to 1.5mL EP tubes and washed three to five times with M9 buffer, leaving about 100μL at the end. Subsequently, 0.1μL of ROS probe H2DCFDA was added to each EP tube and incubated at 37°C for 3h, during which the bottom of the tube was flicked at intervals to ensure uniform mixing; thereafter, it was washed again with M9 buffer to remove excess probe; 2% agarose gel was prepared and dropped on a glass slide, and covered with another glass slide to remove bubbles; after the agar solidified and cooled, the upper glass slide was removed and 40μL was dropped M9 buffer was added to the probe-loaded nematodes, and then the coverslip was lightly covered; finally, a fluorescence microscope was used to observe and photograph a single nematode at a uniform exposure value (excitation wavelength 488 nm, emission wavelength 525 nm);

[0053] Determination of CL4176 nematode lifespan: On the 4th day after synchronization, the nematodes have grown into adults; pick nematodes of the same size and place them into NGM medium supplemented with 25mmol / L ET for culture, and use ordinary NGM medium as the control group; add 100μg / mL of pentafluorouracil to the culture medium to prevent CL4176 nematodes from laying eggs. The synchronized nematodes were randomly divided into 4 groups, namely a blank group (0mmol / L) and an ET-treated group (1mmol / L, 5mmol / L, and 25mmol / L); about 60 nematodes per plate were cultured in a 16°C incubator; the hatching of nematode eggs was recorded as the 0th day of the nematode life, and the end of the nematode life was recorded when there was no reaction when the worm body was lightly probed with platinum wire. The time from the beginning to the end of life was recorded as the nematode lifespan;

[0054] In the above implementation process, Caenorhabditis elegans CL4176 was used as a model of Aβ-induced toxicity in Alzheimer's disease, and the results obtained were as follows: Figure 1 As shown. Figure 1 (a) It can be seen that compared with the control group, the paralysis rates of nematodes in the three treatment groups at 5 mmol / L concentration were different. The paralysis rates of the LP, LNT and ET treatment groups decreased by 33.72%, 19.45% and 63.92%, respectively, and the paralysis rate of the ET treatment group decreased most significantly; this indicates that among the three shiitake mushroom components, ET has a significant alleviating effect on the occurrence of nematode paralysis at this concentration.

[0055] The effects of different concentrations of ET on the paralysis rate of CL4176 nematodes are shown in Figure 1 (b) It can be seen that with the increase of ET concentration, the paralysis rate of CL4176 nematodes decreased significantly, showing a concentration gradient effect, that is, the paralysis rate of nematodes in the 1mmol / L, 5mmol / L, and 25mmol / L treatment groups decreased by 22.5%, 62.5%, and 76.25%, respectively, compared with the control group.

[0056] As can be seen from Figure 1(c), the expression of Aβ in CL4176 nematodes leads to an increase in the level of ROS in the nematodes, while the production of ROS in the nematodes treated with 25mmol / L ET is significantly reduced, proving that ET has an antioxidant effect in nematodes.

[0057] from Figure 1 (d) It can be seen that the lifespan of CL4176 nematodes increased in a dose-dependent manner with the concentration of ET, especially the highest concentration (5mmol / L and 25mmol / L) showed a significant effect; compared with the control group, the average lifespan of the nematodes in the 5mmol / L concentration treatment group was significantly extended, with an average lifespan increase of 29.17%. At the same time, the 25mmol / L concentration treatment group showed a more significant lifespan extension effect, with an average lifespan extended by 39.58% compared with the control group.

[0058] Example 2

[0059] The protective effect of ergothioneine on H2O2-induced damage in human microglial HMC3 cells:

[0060] HMC3 cells were first pretreated with different concentrations of ET for 2 h, and then exposed to different concentrations (40, 60, 80, 100 μmol / L) of H2O2 for 24 h to induce oxidative damage. Cell viability was measured by the cell counting kit CCK-8. HMC3 cells were seeded in a 96-well plate at a density of 1×104 cells / well overnight, and then the culture medium was removed. ET or H2O2 was added to treat the cells for a certain period of time according to the experimental design; after the cell culture medium was discarded, fresh culture medium was added to each well together with 10% CCK-8 and incubated at 37°C for 2 h. The absorbance at 450 nm was then measured using a microplate reader. Cell viability was expressed as a percentage of control cell viability. The data represent three independent experiments (n=3). Cell morphological changes were observed under a microscope and photographed with an inverted optical microscope;

[0061] The results obtained from the above implementation process are as follows Figure 2 As shown in the figure, it can be seen that the stimulation of H2O2 significantly reduced the viability of HMC3 cells, while the pretreatment of ET significantly enhanced the cell survival rate in a dose-dependent manner. The survival rates of cells without ET treatment after stimulation with 40, 60, 80 and 100 μmol / L H2O2 were approximately 68.31%, 44.85%, 29.64% and 26.57%, respectively. After pretreatment with 150 to 600 μmol / L ET, the cell viability induced by 40 μmol / L H2O2 had been significantly reduced, and the survival rates were increased to 84.88%, 86.81% and 92.12%, respectively; when HMC3 cells were stimulated with 60 μmol / L H2O2, pretreatment with 150, 300 and 600 μmol / L ET concentrations could reduce the cell mortality by 11.43%, 25.05% and 37.66%, respectively; compared with 100 μmol / L The cell viability rate after H2O2 treatment was 26.57%. Pretreatment with ET at 150 to 2400 μmol / L effectively slowed down the decrease in cell viability induced by H2O2 at this concentration. Especially after pretreatment with high concentrations of ET (1200, 2400 μmol / L), the cells showed a viability level similar to that of normal cells.

[0062] The protective effect of ET on HMC3 cells induced by H2O2 was clearly confirmed by morphological observation under phase contrast microscope. Figure 3 As shown, it can be seen that the cells in the blank group showed good adhesion, the cells were plump and had clear edges. In contrast, the number of cells in the H2O2-treated group decreased significantly, the intercellular spaces increased, the cells shrank, and most of the cells showed signs of apoptosis; however, the morphology of the cell group pretreated with ET gradually recovered to a level close to that of the blank group after H2O2 induction. With the increase of ET concentration, the cell morphology further tended to normal, and the number of apoptotic cells decreased significantly.

[0063] In summary, ET can alleviate H2O2-induced HMC3 cell damage, significantly improve the survival rate of cells under oxidative stress conditions, improve cell morphology, reduce the number of apoptotic cells, and has a significant protective effect.

[0064] Example 3

[0065] The improvement effect of ergothioneine intake on Alzheimer's symptoms in APP / PS1 mice:

[0066] SPF grade 3-month-old APP / PS1 double transgenic male mice and C57BL / 6 wild-type littermate control male mice were selected. The breeding environment was a standard animal room. All experimental animals were raised in single cages at the Institute of Basic and Translational Medicine of a medical school. All experimental animals were provided with standard feed and purified water, and they were free to eat and drink. The humidity was controlled at 60±5%, the temperature was 22±2℃, and the light-dark cycle was 12h / 12h. After 1 week of adaptive breeding, all mice were ear-tagged and numbered, and randomly divided into four groups (n=10), namely, wild-type littermate control group (WT group, drinking purified water); APP / PS1 group (AD group, drinking purified water), ET low-dose treatment group (AD-LET group, drinking water containing ET 20mg / kg / day), and ET high-dose treatment group (AD-HET group, drinking water containing ET 40mg / kg / day). According to the weight and water intake of mice, ET was prepared every 3 days. ET dietary intervention continued during the behavioral test, and the intervention lasted for a total of 6 months. The test results are as follows: Figure 4 As shown;

[0067] Y-maze: A test to assess the ability of an animal to remember and avoid entering an arm it has explored before; if a mouse can avoid repeatedly exploring a path it has already explored and enter three different arms in a row, which is considered a correct spontaneous alternation, it can be considered to have good spatial learning and memory abilities. Figure 5 As shown;

[0068] Open field test: aims to evaluate the animal's anxiety behavior, exploratory behavior and autonomous activity ability. In this experiment, mice are placed in an open, quadrilateral open field to observe their behavioral responses in an environment without obvious clues or threats; the behavior of the mice, especially their exploratory activities in the central area of ​​the open field and their approach behavior close to the wall (spending a lot of time close to the wall of the open field as an anxiety-like reaction), are used to evaluate their autonomous exploratory behavior ability and anxiety level. The total distance of open field movement can be used as an indicator to measure the mouse's autonomous activity level and confident exploration tendency; a higher total movement distance usually reflects that the mouse has a lower anxiety level and a stronger desire to explore, while a lower total movement distance may indicate a higher anxiety state and inhibition of exploratory behavior. The results are as follows: Figure 6 As shown;

[0069] Novel object recognition experiment: It is a behavioral method to verify cognitive memory. In this experiment, mice are first exposed to two specific objects for exploration. After a certain time interval, one of the original objects will be replaced by a new object. If the mouse's memory function is normal, it will be able to recognize the new object and spend more time exploring the new object relative to the familiar object; the extension of the exploration time of the new object indicates that the mouse has a better memory retention ability and can distinguish between new and old objects, which reflects its strong cognitive function and learning ability; the results are as follows Figure 7 As shown;

[0070] HE staining (hematoxylin-eosin staining): It is a commonly used histopathological staining method used to observe and evaluate detailed information of tissue structure; hematoxylin stains the cell nucleus in blue-purple, and eosin stains the cytoplasm and other structural components in red; this staining method can clearly show the morphology of the cell nucleus and the general condition of the cytoplasm, and is often used to determine whether there are pathological changes in the cells; Nissl staining is another commonly used neural tissue-specific staining technique that can clearly mark the cell nucleus and cytoplasm of neurons, especially Nissl bodies; HE staining and Nissl staining were used to observe the damage of neurons in the brain tissue of APP / PS1 mice; Figure 8 , 9 As shown;

[0071] Thioflavin S staining is a classic histological technique that specifically binds to β-amyloid protein. This staining method can clearly mark the distribution and density of Aβ plaques. Amyloid protein Aβ deposition is considered to be a key factor in the pathogenesis of AD; Aβ plaques are mainly present in the cortex and hippocampus of patients' brains. Immunofluorescence staining technology can identify and visualize these plaques with the help of specific antibodies. In this study, Thioflavin S and Aβ plaque-specific antibodies were used to mark the Aβ deposition in the brain tissues of each group of mice. The staining results are shown in Figure 2. Fig.10 , 11 As shown;

[0072] The activation of microglia plays a core role in neuroinflammation. When overactivated, they will switch from an anti-inflammatory phenotype to a pro-inflammatory phenotype, thereby producing a large number of inflammatory factors, which will further aggravate Aβ deposition and promote the progression of AD. Therefore, the activation of microglia in the brain was evaluated by staining the microglia-specific marker ionized calcium binding adaptor molecule 1 (Iba-1). The average fluorescence intensity of Iba-1 in the brain tissue of each group of mice is shown in Figure 2. Fig.12 shown.

[0073] Both oxidative stress and inflammation are related to the pathogenesis of AD; the above results show that ET dietary intervention significantly reduced the excessive activation of microglia in the brain tissue of mice; the activation of microglia plays a core role in neuroinflammation. At the same time, oxidative stress and inflammation are both related to the pathogenesis of AD. ET is expected to reduce oxidative stress as a strong antioxidant; therefore, GAPDH was used as the internal reference protein, and the WB method was used to detect the expression of antioxidant and inflammation-related proteins in the brain tissue of each group of mice; the results are shown in Fig.13 shown.

[0074] from Figure 4 It can be seen that compared with the WT group, there was no significant change in the body weight of mice in the AD, AD-LET and AD-HET experimental groups, and there was no significant difference in the amount of water consumed by mice in each group; this shows that the intake of ET through drinking water has no significant effect on the body weight and daily water intake of mice; in addition, the organ ratios of the heart, liver, spleen, lung and kidney of mice were calculated, and there was no significant difference among the groups (P>0.05), which indicates that 6 months of ET dietary intervention has no adverse effects on the weight gain, water intake and organ ratios of major organs of mice.

[0075] from Figure 5It can be seen that with the increase of age, the spatial learning and memory ability of AD mice decreased significantly (P<0.05). At 3 months of age, there was no significant difference in the alternation success rate of AD and WT mice in the Y maze test; with the increase of age, the alternation success rate of AD mice decreased to 56.5%, 50.7% and 43.3% at 3, 6 and 9 months of age, respectively; 9-month-old AD mice were slow in the Y maze and showed more frequent grooming behavior; the alternation success rate of 6-month-old AD mice was significantly lower than that of the WT group (P<0.01), indicating that with the increase of age, the spatial learning and memory ability of AD mice was impaired; and AD mice of the same age showed a significant improvement trend after ET dietary intervention; especially 40 mg / kg The alternation success rate of AD-HET mice treated with ET diet was significantly higher than that of the AD group without intervention (P<0.05); the alternation success rate of 9-month-old AD mice was significantly lower than that of the WT group, which further confirmed the trend of decreased spatial cognitive function of AD mice with age; the alternation success rates of AD-LET and AD-HET groups treated with ET diet were significantly increased compared with the AD group (P<0.01); the results of the Y-maze test showed that ET diet intervention had a significant improvement on the spatial learning and memory ability of AD model mice.

[0076] In the open field experiment, Figure 6 The movement trajectories of the mice showed that after entering the open environment, the mice moved less in the central area of ​​the open field, and preferred to move around the open field box; there was no significant difference in the total movement distance of 3-month-old WT and AD group mice in the open field; compared with 3-month-old and 6-month-old AD group mice, the total movement distance of 9-month-old AD mice in the open field was significantly reduced (P<0.05), and their overall performance in the open field was relatively sluggish; compared with the 9-month-old AD group, the total movement distance of the AD-HET group mice of the same age who were intervened by 40 mg / kg ET diet was significantly increased (P<0.05), which indicates that ET can improve the autonomous activity ability of AD mice.

[0077] like Figure 7 As shown in the data, there was no significant difference in the exploration time of novel objects between 3-month-old WT and AD mice, but the exploration time of novel objects by AD mice showed a gradually decreasing trend with the increase of age, and the exploration time of novel objects by 9-month-old AD mice was significantly lower than that by 3-month-old (P<0.05); compared with the WT group, the exploration time of novel objects by 6-month-old and 9-month-old AD mice was significantly reduced (P<0.01); compared with the AD mice, after ET diet intervention, the exploration time of novel objects by 6-month-old and 9-month-old AD-LET and AD-HET mice increased, and the exploration time of novel objects by AD-HET mice was significantly increased; in summary, ET intake can improve the cognitive function and learning ability of AD mice.

[0078] HE staining results of mouse brain tissue Figure 8 As shown, in the cerebral cortex and hippocampus of WT mice, the neurons maintained regular and neat arrangement, with clear cell outlines, distinct boundaries between the nucleus and cytoplasm, and no obvious pathological changes; compared with the WT group, the neurons in the hippocampus of AD mice were arranged irregularly, with reduced density and darker staining of the neuronal nuclei; in the cerebral cortex, the nuclear staining in some areas also became darker, indicating that the neurons in these areas were also damaged or in a state of degeneration; in the AD-LET and AD-HET groups that received ET diet intervention, the neurons in the hippocampus of mice were arranged more regularly and the cell morphology was more normal.

[0079] Nissl staining results Fig. 9 As shown, the Nissl bodies of neurons in the brain tissue of mice are dark blue. The main function of Nissl bodies is related to the synthesis and repair activities of neurons, especially playing an important role in the synthesis of neurotransmitters; their number and health status usually reflect the metabolic activity and health status of neurons. When nerve cells are damaged, the number of Nissl bodies will decrease or even disappear. By observing the changes in Nissl bodies, we can indirectly understand the functional state of neurons and evaluate the intervention effect of ET on AD; the neurons of WT group mice showed a healthy state, with a large number of Nissl bodies, dark blue color, uniform distribution, and clear cell nuclei; the brain tissue of AD group mice, especially the number of Nissl bodies in the cortex and hippocampus, was significantly reduced, and the color was relatively light; in the DG area of ​​the hippocampus, the significant reduction in the number of Nissl bodies was particularly prominent, which is direct evidence of neuronal damage and loss of function; in the AD-LET and especially AD-HET groups, the number of Nissl bodies in the cortex and hippocampal DG areas increased significantly, and the deepening of the color of Nissl bodies indicated that the internal structure and function of neurons were restored or protected to a certain extent.

[0080] like Fig.10 As shown in the figure, thioflavin staining showed that the expression of Aβ in the brain tissue of WT mice was extremely low and almost undetectable. In contrast, the AD model mice showed a significant increase in thioflavin S positive signals. The increase in this signal reflected the significant increase in Aβ plaques, especially in the hippocampus and cortex tissues. In addition, the results of immunofluorescence staining using Aβ plaque-specific antibodies also showed a significant increase in the number and area of ​​Aβ plaques in the brain tissue of AD mice ( Fig.11 b); After ET dietary intervention, the number and area of ​​Aβ plaques in the AD-LET and AD-HET groups of mice were significantly reduced, among which the effect in the AD-HET group was the most obvious, and the expression and fluorescence intensity of Aβ were significantly lower than those in the AD group of mice; this indicates that ET dietary intervention has a significant effect on reducing the deposition of Aβ in the brain, especially in the AD-HET group; Fig.11As shown in (a), compared with the WT group, the average fluorescence intensity of Aβ in the AD model group mice was significantly increased (P<0.01), while after ET treatment, the fluorescence intensity of both the AD-LET and AD-HET groups was significantly decreased (P<0.05), especially in the AD-HET group, where the Aβ fluorescence intensity was the lowest among all groups, which further confirmed the potential neuroprotective effect of ET. In summary, the results of thioflavin staining and Aβ plaque-specific antibody labeling corroborated each other, indicating that ET played a significant intervention role in Aβ deposition in mouse brain tissue.

[0081] like Fig.12 As shown in the figure, compared with other groups such as WT, the average fluorescence intensity of Iba-1 in the brain tissue of mice in the AD group was significantly enhanced (P<0.05); after ET diet intervention, the fluorescence intensity of both AD-LET and AD-HET groups was significantly lower than that of the AD group (P<0.05), while there was no significant difference in the fluorescence intensity of Iba-1 between the AD-LET and AD-HET groups; Fig.12 As shown in (b), there were more Iba-1 positive microglia in the brain tissue of the AD group mice compared with the WT group mice. Compared with the AD group, the number of Iba-1 positive microglia in the cortex and hippocampus of the brain tissue of the ET diet intervention group mice decreased, and the number of Iba-1 positive microglia in the brain tissue of the AD-HET group mice was the least; in summary, it was shown that the ET diet intervention reduced the excessive activation of microglia in the brain tissue of APP / PS1 mice.

[0082] Fig.13 a shows the expression levels of Nrf2, HO-1, NQO1, TNF-α, and IL-1β proteins in the brain tissues of mice in different treatment groups; Fig.13 As shown in (b), (c) and (d), the expressions of NRF2, HO-1 and NQO1 proteins related to antioxidant activity were not statistically different among the four groups of mice (P<0.05). Compared with the WT group, the expression of HO-1 in the brain tissue of the AD-LET and AD-HET groups after ET diet intervention showed an upward trend, but the difference was not significant (P<0.05). Compared with the AD group, the expression of NQO1 in the AD-LET group was increased, but the difference was also not significant (P<0.05). The expressions of inflammatory markers TNF-α and IL-1β were shown in Fig.13As shown in (e) and (f), compared with the WT group, the expression of TNF-α in the brain tissue of the AD group mice was significantly increased (P<0.05), and the AD-HET group could significantly reduce the expression of TNF-α in the brain tissue of APP / PS1 mice after ET diet intervention (P<0.05); IL-1β had an increasing trend in the brain tissue of AD mice, but there was no significant difference in the expression of IL-1β in the brain tissue of the four groups of mice (P<0.05). In general, although ET has limited effect on the expression of antioxidant proteins, it has a significant effect on reducing the expression of inflammatory marker TNF-α (P<0.05).

[0083] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. An evaluation method for improving Alzheimer's disease by ergothioneine, characterized in that, Verify the inhibitory effects of ergothioneine on Aβ-induced toxicity and H2O2-induced cell damage, and demonstrate the ability of ergothioneine to prevent and alleviate Alzheimer's disease.

2. a kind of ergothioneine according to claim 1 improves the evaluation method of Alzheimer's disease, it is characterised in that, When inhibiting Aβ-induced toxicity, the ergothioneine is used at a concentration of 1 to 25 mmol / L.

3. a kind of ergothioneine according to claim 1 improves the evaluation method of Alzheimer's disease, it is characterised in that, Inhibited H2O2-induced cell damage, improved cell morphology and reduced the number of apoptotic cells.

4. a kind of ergothioneine according to claim 1 improves the evaluation method of Alzheimer's disease, it is characterised in that, The cells are microglia.

5. a kind of ergothioneine according to claim 1 improves the evaluation method of Alzheimer's disease, it is characterised in that, When inhibiting H2O2-induced cell damage, the concentration of ergothioneine used was 150-2400 μmol / L.

6. a kind of ergothioneine according to claim 1 improves the evaluation method of Alzheimer's disease, it is characterised in that, It also includes verifying the effects of ergothioneine in inhibiting the expression of inflammatory markers, inhibiting nerve cell damage and improving cognitive learning ability.

7. a kind of ergothioneine according to claim 6 improves the evaluation method of Alzheimer's disease, it is characterised in that, The usage concentration of the ergothioneine is 20 to 40 mg / kg / day.

8. Application of ergothioneine in the preparation of anti-Alzheimer's disease drugs.

9. The application of ergothioneine according to claim 8 in making anti-Alzheimer's disease drugs, characterized in that, The dosage form of the drug includes one or more of tablets, capsules, granules, solutions or injections.

10. The use of ergothioneine according to claim 8 in making anti-Alzheimer's disease drugs, characterized in that, The dosage of ergothioneine in the tablet, capsule, granule, solution or injection is 160-1280 mg / kg / day.

Citation Information

Patent Citations

  • Methods and compositions related to use of ergothioneine

    CN116528854A

  • Composition of stem cell extracellular vesicles containing ergothioneine and application thereof

    CN117298152A

  • Anti-aging composition and preparation method thereof

    CN117838558A

  • Composition for inhibiting increase of phosphorized protein tau caused by amyloid β

    JP2023179383A

Cited By

  • Composition and method

    WO2026108847A1